Porton Pharma Solutions' (SHE:300363) unit, Suzhou Porton Biopharmaceutical, obtained a pharmaceutical manufacturing license from the Jiangsu Provincial Medical Products Administration, according to a Shenzhen bourse filing on Monday.
The Chinese biotech company's shares jumped 14% at the close of Tuesday's trade.
Suzhou Porton's manufacturing scope includes therapeutic biological products.
The license is valid until July 26, 2031.